Literature DB >> 20924622

New potent biphalin analogues containing p-fluoro-L-phenylalanine at the 4,4' positions and non-hydrazine linkers.

Adriano Mollica1, Francesco Pinnen, Federica Feliciani, Azzurra Stefanucci, Gino Lucente, Peg Davis, Frank Porreca, Shou-Wu Ma, Josephine Lai, Victor J Hruby.   

Abstract

We report the synthesis and the biological evaluation of two new analogues of the potent dimeric opioid peptide biphalin. The performed modification is based on the replacement of two key structural elements of the native biphalin, namely: the hydrazine bridge which joins the two palindromic moieties and the phenylalanine residues at the 4,4' positions of the backbone. The new analogues 9 and 10 contain 1,2-phenylenediamine and piperazine, respectively, in place of the hydrazidic linker and p-fluoro-L-phenylalanine residues at 4 and 4' positions. Binding values are: Kμ(i)=0.51 nM and Kδ(i)=12.8 nM for compound 9, Kμ(i)=0.09 nM and Kδ(i)=0.11 nM for analogue 10.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20924622      PMCID: PMC5689474          DOI: 10.1007/s00726-010-0760-7

Source DB:  PubMed          Journal:  Amino Acids        ISSN: 0939-4451            Impact factor:   3.520


  23 in total

1.  Structure-activity relationships of methionine-enkephalin.

Authors:  B A Morgan; C F Smith; A A Waterfield; J Hughes; H W Kosterlitz
Journal:  J Pharm Pharmacol       Date:  1976-08       Impact factor: 3.765

2.  Synthesis and biological evaluation of new biphalin analogues with non-hydrazine linkers.

Authors:  Adriano Mollica; Peg Davis; Shou-Wu Ma; Josephine Lai; Frank Porreca; Victor J Hruby
Journal:  Bioorg Med Chem Lett       Date:  2005-05-16       Impact factor: 2.823

3.  Modifications of the 4,4'-residues and SAR studies of Biphalin, a highly potent opioid receptor active peptide.

Authors:  G Li; W Haq; L Xiang; B S Lou; R Hughes; I A De Leon; P Davis; T J Gillespie; M Romanowski; X Zhu; A Misicka; A W Lipkowski; F Porreca; T P Davis; H I Yamamura; D F O'Brien; V J Hruby
Journal:  Bioorg Med Chem Lett       Date:  1998-03-03       Impact factor: 2.823

4.  [D-Pen2,D-Pen5]enkephalin analogues with increased affinity and selectivity for delta opioid receptors.

Authors:  G Toth; T H Kramer; R Knapp; G Lui; P Davis; T F Burks; H I Yamamura; V J Hruby
Journal:  J Med Chem       Date:  1990-01       Impact factor: 7.446

5.  Antinociceptive profile of biphalin, a dimeric enkephalin analog.

Authors:  P J Horan; A Mattia; E J Bilsky; S Weber; T P Davis; H I Yamamura; E Malatynska; S M Appleyard; J Slaninova; A Misicka
Journal:  J Pharmacol Exp Ther       Date:  1993-06       Impact factor: 4.030

6.  Dimeric tetrapeptide enkephalins display extraordinary selectivity for the delta opiate receptor.

Authors:  Y Shimohigashi; T Costa; H C Chen; D Rodbard
Journal:  Nature       Date:  1982-05-27       Impact factor: 49.962

7.  Double-enkephalins--synthesis, activity on guinea-pig ileum, and analgesic effect.

Authors:  A W Lipkowski; A M Konecka; I Sroczyńska
Journal:  Peptides       Date:  1982 Jul-Aug       Impact factor: 3.750

8.  Blood-to-central nervous system entry and stability of biphalin, a unique double-enkephalin analog, and its halogenated derivatives.

Authors:  T J Abbruscato; S A Williams; A Misicka; A W Lipkowski; V J Hruby; T P Davis
Journal:  J Pharmacol Exp Ther       Date:  1996-03       Impact factor: 4.030

9.  Identification of two related pentapeptides from the brain with potent opiate agonist activity.

Authors:  J Hughes; T W Smith; H W Kosterlitz; L A Fothergill; B A Morgan; H R Morris
Journal:  Nature       Date:  1975-12-18       Impact factor: 49.962

10.  Comparison of mu-, delta- and kappa-receptor binding sites through pharmacologic evaluation of p-nitrophenylalanine analogs of opioid peptides.

Authors:  P W Schiller; T M Nguyen; J DiMaio; C Lemieux
Journal:  Life Sci       Date:  1983       Impact factor: 5.037

View more
  6 in total

1.  Biological active analogues of the opioid peptide biphalin: mixed α/β(3)-peptides.

Authors:  Adriano Mollica; Francesco Pinnen; Roberto Costante; Marcello Locatelli; Azzurra Stefanucci; Stefano Pieretti; Peg Davis; Josephine Lai; David Rankin; Frank Porreca; Victor J Hruby
Journal:  J Med Chem       Date:  2013-04-12       Impact factor: 7.446

2.  The cis-4-amino-L-proline residue as a scaffold for the synthesis of cyclic and linear endomorphin-2 analogues.

Authors:  Adriano Mollica; Francesco Pinnen; Azzurra Stefanucci; Federica Feliciani; Cristina Campestre; Luisa Mannina; Anatoly P Sobolev; Gino Lucente; Peg Davis; Josephine Lai; Shou-Wu Ma; Frank Porreca; Victor J Hruby
Journal:  J Med Chem       Date:  2012-03-22       Impact factor: 7.446

3.  Developing Cyclic Opioid Analogues: Fluorescently Labeled Bioconjugates of Biphalin.

Authors:  Azzurra Stefanucci; Marilisa Pia Dimmito; Gabriela Molnar; John M Streicher; Ettore Novellino; Gokhan Zengin; Adriano Mollica
Journal:  ACS Med Chem Lett       Date:  2020-01-08       Impact factor: 4.345

4.  Novel Cyclic Biphalin Analogues by Ruthenium-Catalyzed Ring Closing Metathesis: in Vivo and in Vitro Biological Profile.

Authors:  Azzurra Stefanucci; Wei Lei; Stefano Pieretti; Marilisa Pia Dimmito; Grazia Luisi; Ettore Novellino; Michał Nowakowski; Wiktor Koźmiński; Sako Mirzaie; Gokhan Zengin; John M Streicher; Adriano Mollica
Journal:  ACS Med Chem Lett       Date:  2019-03-08       Impact factor: 4.345

5.  Opioid Receptor Activity and Analgesic Potency of DPDPE Peptide Analogues Containing a Xylene Bridge.

Authors:  Azzurra Stefanucci; Ettore Novellino; Sako Mirzaie; Giorgia Macedonio; Stefano Pieretti; Paola Minosi; Edina Szűcs; Anna I Erdei; Ferenc Zádor; Sándor Benyhe; Adriano Mollica
Journal:  ACS Med Chem Lett       Date:  2017-03-14       Impact factor: 4.345

6.  Cyclic biphalin analogues with a novel linker lead to potent agonist activities at mu, delta, and kappa opioid receptors.

Authors:  Michael Remesic; Giorgia Macedonio; Adriano Mollica; Frank Porreca; Victor Hruby; Yeon Sun Lee
Journal:  Bioorg Med Chem       Date:  2018-05-26       Impact factor: 3.641

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.